Healionics develops the _STARgraft_ synthetic vascular graft, which utilizes a Sphere Templated Angiogenic Regeneration biomaterial to enhance blood access for dialysis patients. This technology significantly reduces the risks of occlusion and infection associated with traditional grafts, improving patient outcomes and lowering treatment costs.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with kidney failure require frequent dialysis, but current methods for accessing the bloodstream for dialysis are prone to occlusion and infection. Existing synthetic vascular grafts often fail, leading to increased healthcare costs and reduced patient quality of life.
Solution
Healionics develops the _STARgraft_ synthetic vascular graft, designed to improve blood access for dialysis patients. The _STARgraft_ utilizes the Sphere Templated Angiogenic Regeneration (_STAR_) biomaterial scaffold, engineered with a specific pore size and structure to promote angiogenesis and tissue regeneration. This unique biomaterial minimizes foreign body response and tissue scarring, while also providing high resistance to infection. The _STARgraft_ aims to provide a safer, more reliable, and cost-effective means of bloodstream access for dialysis.
Target Audience
The primary target audience includes patients with kidney failure requiring hemodialysis and the clinicians who treat them, including nephrologists and vascular surgeons.
Features
- Utilizes the proprietary _STAR_ (Sphere Templated Angiogenic Regeneration) biomaterial scaffold
- Designed to promote angiogenesis (formation of new blood vessels)
- Engineered to minimize foreign body response and tissue scarring
- Provides high resistance to infection
- Aims to improve the health, longevity, and quality of life for kidney failure patients